Europe
Genmab just received a $20M milestone payment from Janssen Biotech.
On Wednesday, KBR reported that a male employee at Novartis Korea reported to the company that his female boss sexually harassed him in September.
The company’s head of Development, Joerg Moeller, is taking the reins of the company’s new R&D program.
Sanofi’s setback could open the door for rival drugmaker Takeda.
The firm said it sold the shares at an issue price of €12.50 each, and that the total 6.4 million shares represent approximately 14.3 percent of its outstanding shares.
What many hope will be the final chapter in an unfortunate saga in multiple sclerosis research appears to have been written by the scientist who started the affair in the first place.
With the $63.5B takeover of Monsanto by Bayer taking longer than expected, and a key patent for Xarelto expiring in 2024, Bayer’s execs are finding themselves defending their decisions.
AM-111 failed to meet its primary endpoint, although the company is putting a positive spin on it by noting it was effective in a subpopulation.
Genentech’s Hemlibra just got approved but is expected to bring in around $2 billion in peak sales.
PRESS RELEASES